- Home
- NAOV vs XXII Comparison
NAOV vs XXII Comparison
Compare NAOV & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAOV
- XXII
- Stock Information
- Founded
- NAOV 2003
- XXII 1998
- Country
- NAOV United States
- XXII United States
- Employees
- NAOV N/A
- XXII N/A
- Industry
- NAOV Industrial Specialties
- XXII Medicinal Chemicals and Botanical Products
- Sector
- NAOV Health Care
- XXII Health Care
- Exchange
- NAOV Nasdaq
- XXII Nasdaq
- Market Cap
- NAOV 2.4M
- XXII 2.0M
- IPO Year
- NAOV N/A
- XXII N/A
- Fundamental
- Price
- NAOV $0.92
- XXII $3.33
- Analyst Decision
- NAOV
- XXII
- Analyst Count
- NAOV 0
- XXII 0
- Target Price
- NAOV N/A
- XXII N/A
- AVG Volume (30 Days)
- NAOV 3.0M
- XXII 2.6M
- Earning Date
- NAOV 08-13-2025
- XXII 08-12-2025
- Dividend Yield
- NAOV N/A
- XXII N/A
- EPS Growth
- NAOV N/A
- XXII N/A
- EPS
- NAOV N/A
- XXII N/A
- Revenue
- NAOV $2,662,000.00
- XXII $23,869,000.00
- Revenue This Year
- NAOV N/A
- XXII $22.41
- Revenue Next Year
- NAOV N/A
- XXII $76.35
- P/E Ratio
- NAOV N/A
- XXII N/A
- Revenue Growth
- NAOV N/A
- XXII N/A
- 52 Week Low
- NAOV $0.67
- XXII $2.86
- 52 Week High
- NAOV $16.25
- XXII $2,390.85
- Technical
- Relative Strength Index (RSI)
- NAOV 40.36
- XXII 23.05
- Support Level
- NAOV $0.89
- XXII $2.86
- Resistance Level
- NAOV $1.08
- XXII $3.40
- Average True Range (ATR)
- NAOV 0.07
- XXII 0.84
- MACD
- NAOV 0.03
- XXII 0.26
- Stochastic Oscillator
- NAOV 52.29
- XXII 7.11
About NAOV NanoVibronix Inc.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.